Cat. No.: HY-156027

SIRT6-IN-3

Customer Review

Based on 1 Customer Validation

SIRT6-IN-3 (compound 8a) is a selective inhibitor of SIRT6 (IC₅₀=7.49 μM). SIRT6-IN-3 inhibits pancreatic ductal adenocarcinoma (PDAC) cells proliferation and induces apoptosis. SIRT6-IN-3 increases the sensitivity of cancer cells to gemcitabine (HY-17026) via blocking the DNA damage repair pathway. SIRT6-IN-3 is used in pancreatic cancer research.

For research use only. We do not sell to patients.

Purity: 98.19%
CAS No.: 3023471-40-8
Formula: C₂₁H₃₀Br₃ClN₆S
Molecular Weight:673.73

Storage:

4°C, protect from light, stored under nitrogen

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)

SIRT6-IN-3 Chemical Structure

CAS No.: 3023471-40-8

Size

Price

Stock

Quantity

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Bulk Inquiry

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Solvent & Solubility
- In Vitro
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

IC₅₀ & Target

SIRT1

80.52 μM (IC₅₀)

SIRT2

92.21 μM (IC₅₀)

SIRT6

7.46 μM (IC₅₀)

HDAC3

111.9 μM (IC₅₀)

HDAC6

96.77 μM (IC₅₀)

HDAC8

102 μM (IC₅₀)

All Sirtuin Isoforms :

All HDAC Isoforms :

All Akt Isoforms :

All mTOR Isoforms :

All Ribosomal S6 Kinase (RSK) Isoforms :

All ERK Isoforms :

In Vitro

SIRT6-IN-3 (25 μM, 48 h) induces PDAC cell-cycle arrest and apoptosis^[1].
SIRT6-IN-3 (25 μM, 72 h) inhibits the proliferation of pancreatic cancer cells by inhibiting signaling pathways^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis^[1]

Cell Line:

PDAC cells
Concentration:

0, 6.25, 12.5, 25 μM
Incubation Time:

48 h
Result:

Increased the percentages of the G0-G1 phase and decreased cyclin D1 expression in a dose-dependent manner.

Western Blot Analysis^[1]

Cell Line:

PDAC cells
Concentration:

0, 6.25, 12.5, 25 μM
Incubation Time:

Overnight
Result:

Significantly down-regulated p-mTOR, p-P70S6K, p-AKT, and p-ERK.
Inhibited the activity of both mTORC1 and mTORC2.
Significantly up-regulated the expression of cleaved-PARP, cleaved-Caspase3, and cleaved-Caspase9.

In Vivo

SIRT6-IN-3 (HY-156027; 20 mg/kg for i.p; once every 2 days for 4 weeks) has antitumor effects on tumor mouse model^[1].
SIRT6-IN-3 (HY-156027; 20 mg/kg for i.p; once every 2 days for 4 weeks) enhances the antitumor effects of gemcitabine in vivo when in combination with gemcitabine (ratio 2 : 1)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Tumor mouse model^[1]
Dosage:

20 mg/kg (in combination with 10 mg/kg gemcitabine)
Administration:

Intraperitoneal injection (i.p.); Once every 2 days for 4 weeks
Result:

Inhibited the tumor mass 71.3% in mice with combinations of gemcitabine.
Greatly increased the expression of apoptosis maker.

Chemical Information

CAS No. 3023471-40-8
Appearance Solid
Molecular Weight 673.73
Formula C₂₁H₃₀Br₃ClN₆S
Color Light yellow to yellow
SMILES

BrC1=C(Br)NC(C2=NC=CC3=C2N=CN3CCCCCCS/C(N(C)C)=[N+](C)\C)=C1.Cl.[Br-]
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, protect from light, stored under nitrogen

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)

Solvent & Solubility

In Vitro:

DMSO : ≥ 120 mg/mL (178.11 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.4843 mL

7.4214 mL

14.8427 mL

5 mM

0.2969 mL

1.4843 mL

2.9685 mL

10 mM

0.1484 mL

0.7421 mL

1.4843 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (273 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Song N, et al. Discovery of a pyrrole-pyridinimidazole derivative as novel SIRT6 inhibitor for sensitizing pancreatic cancer to gemcitabine. Cell Death Dis. 2023 Aug 4;14(8):499. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.4843 mL	7.4214 mL	14.8427 mL	37.1069 mL
	5 mM	0.2969 mL	1.4843 mL	2.9685 mL	7.4214 mL
	10 mM	0.1484 mL	0.7421 mL	1.4843 mL	3.7107 mL
	15 mM	0.0990 mL	0.4948 mL	0.9895 mL	2.4738 mL
	20 mM	0.0742 mL	0.3711 mL	0.7421 mL	1.8553 mL
	25 mM	0.0594 mL	0.2969 mL	0.5937 mL	1.4843 mL
	30 mM	0.0495 mL	0.2474 mL	0.4948 mL	1.2369 mL
	40 mM	0.0371 mL	0.1855 mL	0.3711 mL	0.9277 mL
	50 mM	0.0297 mL	0.1484 mL	0.2969 mL	0.7421 mL
	60 mM	0.0247 mL	0.1237 mL	0.2474 mL	0.6184 mL
	80 mM	0.0186 mL	0.0928 mL	0.1855 mL	0.4638 mL
	100 mM	0.0148 mL	0.0742 mL	0.1484 mL	0.3711 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

SIRT6-IN-3

Cell Cycle/DNA Damage Compound Library

Epigenetics Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

MAPK Compound Library

PI3K/Akt/mTOR Compound Library

Stem Cell Signaling Compound Library

Histone Modification Research Compound Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Endocrinology Compound Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Glutamine Metabolism Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Glucose Metabolism Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Osteogenesis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Mitochondrial Protection Compound Library

Metabolic Enzyme Compound Library

Highly Selective Inhibitors Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Anti-Brain Cancer Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

High-Efficiency Gene Editing Compound Library

Lactylation Compound Library

All Sirtuin Isoforms

All HDAC Isoforms

All Akt Isoforms

All mTOR Isoforms

All Ribosomal S6 Kinase (RSK) Isoforms

All ERK Isoforms

Biological Activity

Chemical Information

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

SIRT6-IN-3 Related Classifications

Cat. No.: HY-156027